MARKET

IDRA

IDRA

Idera Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.730
0.000
0.00%
Closed 16:00 07/14 EDT
OPEN
1.750
PREV CLOSE
1.730
HIGH
1.750
LOW
1.706
VOLUME
70.65K
TURNOVER
--
52 WEEK HIGH
3.580
52 WEEK LOW
0.8130
MARKET CAP
58.31M
P/E (TTM)
-0.7626
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average IDRA stock price target is 7.60 with a high estimate of 10.00 and a low estimate of 5.00.

EPS

IDRA News

More
Idera Pharmaceuticals Inc (IDRA): Hedge Funds Are Nibbling On
Insider Monkey · 06/22 04:13
CLDR, AGEN among premarket gainers
Seeking Alpha - Article · 06/02 13:21
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
GlobeNewswire · 06/02 13:15
Idera rallies on positive tilsotolimod data
Seeking Alpha - Article · 06/02 12:51
Idera Pharmaceuticals Files For Resale Of 6.1M Shares Of Common Stock By Selling Shareholders
Benzinga · 06/02 12:34
Idera Pharmaceuticals Announces Preliminary Data From And Planned Continuation Of ILLUMINATE-206 Trial For Treatment Of Micro-Satellite Stable Colorectal Cancer
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ:IDRA, the &ldquo, Company&rdquo, )) today announced preliminary data from the first 10 patients in the safety cohort of 
Benzinga · 06/02 12:15
Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
GlobeNewswire · 05/01 13:00
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
GlobeNewswire · 04/30 21:35

Industry

Biotechnology & Medical Research
+2.63%
Pharmaceuticals & Medical Research
+1.70%

Hot Stocks

Symbol
Price
%Change

About IDRA

Idera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology. Using TLR technology, the Company designs synthetic oligonucleotide-based drug candidates to act by modulating the activity of specific TLRs. Using its 3GA technology, the Company is developing drug candidates to turn off the messenger ribo nucleic acid (mRNA) associated with disease causing genes. The Company's drug candidates include IMO-8400, IMO-2125 and IMO-9200. The Company has designed TLR antagonists and agonists to act by modulating the activity of targeted TLRs. It is developing its 3GA technology to turn off the mRNA associated with disease causing genes.
More

Webull offers kinds of Idera Pharmaceuticals Inc stock information, including NASDAQ:IDRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IDRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IDRA stock methods without spending real money on the virtual paper trading platform.